Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

52.14.35.155
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Oncology

Implantable venous access devices outperform PICCs in cancer treatment

Posted on

Amongst patients with malignant bone and soft tissue tumors of the lower extremities, implantable venous access devices (TIVADs) prolong catheter indwelling time, reduce catheter-related complications, and maintain shoulder joint function better than peripherally inserted central catheters (PICC), according to a study.

The study compared 65 cases of TIVADs and 65 cases of PICC in patients diagnosed with malignant bone or soft tissue tumors who received regular chemotherapy. The TIVADs group had better outcomes in terms of catheter indwelling time, catheter-related complications, Constant-Murley score for the catheterization-side shoulder joint, and less displacement of the catheter end position after 180° abduction of the catheterization-side shoulder joint compared to the PICC group at 6 months after catheterization.

Reference
Shan J, Lv S, Li H, et al. A comparative study between two methods of delivery of chemotherapeutic agent in patients with bone and soft tissue sarcoma of lower extremity. BMC Musculoskelet Disord. 2023;24(1):317. doi: 10.1186/s12891-023-06417-7. PMID: 37087416.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-